As we have discussed in previous posts, studies have shown that the ingredients contained in YAZ®, Yasmin® and Ocella® have been linked to various forms of severe Yaz side-effects. Reportedly, these side-effects include: heart attack, stroke, deep vein thrombosis (also known as DVT or blood clots), internal organ damage (including gallbladder damage), myocardial infarction and pulmonary embolism. Recently, a large number of YAZ®, Yasmin® and Ocella® cases have been designated as Mass Tort or Multidistrict Litigation (MDL) cases.

The New Jersey State Courts are currently contemplating granting Mass Tort designation to YAZ®, Yasmin® and Ocella® cases currently pending in New Jersey. The makers of YAZ®, Bayer Healthcare Pharmaceuticals, are headquartered in Wayne, New Jersey. The makers of Ocella®, Barr Pharmaceuticals, are headquartered in Montvale, New Jersey. Similar cases have received MDL treatment in the United States District Court for the Southern District of Illinois, and Mass Tort treatment in Philadelphia County, Pennsylvania. The New Jersey Mass Tort would eventually be venued in Atlantic, Bergen or Middlesex counties.